DJIA 16,987.51 -61.49 -0.36%
NASDAQ 4,567.60 -24.21 -0.53%
S&P 500 1,985.54 -11.91 -0.60%
market minute promo

Allergan, Inc. (NYSE: AGN)

169.25 0.92 (0.55%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AGN $169.25 0.55%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $167.64
Previous Close $168.33
Daily Range $166.83 - $169.61
52-Week Range $87.75 - $174.49
Market Cap $50.3B
P/E Ratio 38.61
Dividend (Yield) $0.20 (0.1%)
Ex-Dividend Date
Dividend Pay Date
08/13/14
09/05/14
Volume 1,443,032
Average Daily Volume 2,165,976
Current FY EPS $5.79

Sector

Healthcare

Industry

Drugs

Allergan, Inc. (AGN) Description

A technology-driven, global health care company which discovers, develops and commercializes pharmaceutical and medical device products for markets such as ophthalmic, neurological, medical aesthetics, medical dermatological etc. Website: http://www.allergan.com/

News & Commentary Rss Feed

3 Questions for Allergan Inc.

Allergan is fighting tooth and nail to remain independent from Valeant Pharmaceuticals. Here are three questions investors should know the answers to heading into what is looking like the endgame.

Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog

Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog

Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval - Analyst Blog

Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog

Allergan Comments On Pershing Square's Delivery Of Additional Requests From Stockholders Owning 1.5%

Allergan Comments On Pershing Square's Delivery Of Additional Requests From Stockholders Owning 1.5% Of Allergan's Shares

Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog

Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog

Bill Ackman Rips Allergan, Inc. In Letter

AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog

Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog

Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog

See More AGN News...

AGN's Top Competitors

AGN $169.25 (0.55%)
Current stock: AGN
JNJ $104.58 (0.03%)
Current stock: JNJ
NVS $93.76 (-0.64%)
Current stock: NVS
RHHBY $36.70 (-0.54%)
Current stock: RHHBY